Akira SUGIYAMA, Takeshi KAWAMURA, Toshiya TANAKA, Hirofumi DOI, Takefumi YAMASHITA, Keiko SHINODA, Hideaki FUJITANI, Kenzo YAMATSUGU, Yohei SHIMIZU, Toshifumi TATSUMI, Kazuki TAKAHASHI, Motomu KANAI, Eiichi MIZOHATA, Tatsuya KAWATO, Takefumi DOI, Tsuyoshi INOUE, Tatsuhiko KODAMA
Proceedings of the Japan Academy, Series B 95 10 602 - 611 2019年12月11日
[査読有り][通常論文] In advanced cancer patients, malignant cells invade and disseminate within normal cells and develop resistance to therapy with additional genetic mutations, which makes radical cure very difficult. Precision medicine against advanced cancer is hampered by the lack of systems aimed at multiple target molecules within multiple loci. Here, we report the development of a versatile diagnostic and therapeutic system for advanced cancer, named the Cupid and Psyche system. Based on the strong non-covalent interaction of streptavidin and biotin, a low immunogenic mutated streptavidin, Cupid, and a modified artificial biotin, Psyche, have been designed. Cupid can be fused with various single-chain variable fragment antibodies and forms tetramer to recognize cancer cells precisely. Psyche can be conjugated to a wide range of diagnostic and therapeutic agents against malignant cells. The Cupid and Psyche system can be used in pre-targeting therapy as well as photo-immunotherapy effectively in animal models supporting the concept of a system for precision medicine for multiple targets within multiple loci.